This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Baxalta Incorporated
Baxalta Incorporated, a leading biopharmaceutical company, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 2015, Baxalta emerged from a spin-off of Baxter International, focusing on innovative therapies for rare diseases and complex conditions. The company is renowned for its specialised products in haemophilia, immunology, and oncology, with offerings such as Adynovate, a unique recombinant factor VIII therapy that enhances patient outcomes. Baxalta has established a strong market position, recognised for its commitment to research and development, which has led to significant advancements in treatment options. With a dedication to improving patient lives, Baxalta continues to be a key player in the biopharmaceutical industry, striving for excellence in every aspect of its operations.
DitchCarbon Score
How does Baxalta Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Baxalta Incorporated's score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Baxalta Incorporated, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which influences its climate commitments and initiatives. Baxalta's climate strategy is aligned with the broader goals set by its parent company, Takeda. This includes commitments to science-based targets (SBTi) and other sustainability initiatives. However, specific reduction targets or achievements for Baxalta itself have not been disclosed. As part of its corporate family relationship, emissions data and climate initiatives are cascaded from Takeda Pharmaceutical Company Limited, which operates at a cascade level of 3. This means that while Baxalta may not have its own distinct emissions data, it adheres to the sustainability framework established by Takeda, which is focused on reducing its overall carbon footprint and enhancing environmental stewardship. In summary, while Baxalta Incorporated does not provide specific emissions data or reduction targets, it is committed to the climate initiatives set forth by its parent company, Takeda Pharmaceutical Company Limited, reflecting a collective effort towards sustainability in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Baxalta Incorporated is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
